Welcome to our dedicated page for Dancann Pharma A/S news (Ticker: DCPXF), a resource for investors and traders seeking the latest updates and insights on Dancann Pharma A/S stock.
DanCann Pharma A/S (DCPXF) is a Danish biopharmaceutical company founded in 2018, focusing on cannabinoid-powered products. Listed on the Spotlight Stock Market in Copenhagen/Stockholm and OTCQB in the USA, the company has recently published its Q2-2023 report, showcasing its growth and development in the industry.DanCann Pharma A/S (OTCQB: DCPXF) announced its Q4 2022 financial report, revealing net sales of DKK 5.707 million, a significant increase from DKK 874,000 in Q4 2021. The operating profit (EBIT) was reported at DKK -17.587 million, worsening from DKK -14.508 million year-over-year. The result per share was DKK -0.25, improving from DKK -0.52 in the previous year. The equity ratio stood at 0.84, reflecting a robust financial position. The total number of shares at year-end was 65.014 million, compared to 28.468 million in 2021. The report emphasizes a favorable growth trajectory despite ongoing challenges.
FAQ
What is the market cap of Dancann Pharma A/S (DCPXF)?
When was DanCann Pharma A/S founded?
Where is DanCann Pharma A/S listed?
What is the focus of DanCann Pharma A/S?
What recent report did DanCann Pharma A/S publish?
Who is the CEO of DanCann Pharma A/S?
